Affiliation:
1. Hospital Universitario La Paz
2. Hospital La Paz Institute for Health Research, La Paz University Hospital
Abstract
Abstract
Patients with inflammatory bowel disease (IBD) treated with biologic and/or immunosuppressant drugs are at increased risk for opportunistic infections. Seroprevalence studies can confirm the diagnosis of SARS-CoV-2 infections as well as the associated risk factors.
This is a descriptive study which primary endpoints were to highlight the prevalence of SARS-CoV-2 antibodies in a cohort of IBD patients, and to analyze seroconversion in patients with known COVID-19 infection and its relationship with IBD treatments.
Patients filled in a questionnaire about symptoms of COVID-19 infection and clinical information about their IBD. All included patients were tested for SARS-CoV-2 antibodies.
392 patients were included. Among patients with clinical infection, 69 patients (17,65%) were IgG-positive, 286 (73,15%) IgG-negative and 36 (9,21%) indeterminate.
In relation to seroconversion among patients under biologic treatment, 13 patients of the 23 with a previous positive CRP developed antibodies (56.5%). However, when the influence of immunosuppressive treatment on the probability of developing antibodies was analyzed, no significant differences were seen between those patients with or without treatment (77.8% vs. 77.1%, p=0.96).
In our cohort of IBD patients, after one year of pandemic, there were 18.64% IgG positive patients, a higher prevalence than the general population (15.7%).
Publisher
Research Square Platform LLC
Reference23 articles.
1. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient;Al-Ani AH;Aliment Pharmacol Ther,2020
2. COVID-19 and Inflammatory Bowel Diseases: Risk Assessment, Shared Molecular Pathways, and Therapeutic Challenges;Popa IV;Gastroenterol Res Pract,2020
3. Brenner EJ, et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology [Internet]. 2020;159(2):481–491.e3. Available from: https://doi.org/10.1053/j.gastro.2020.05.032
4. The risk of SARS-CoV-2 in immunosuppressed IBD patients;Higgins PDR;Crohn’s Colitis 360,2020
5. Outcomes of COVID-19 in 79 patients with IBD in Italy: An IG-IBD study;Bezzio C;Gut,2020